Human therapeutic cocaine vaccine:
safety and immunogenicity

Kosten TR, Rosen M, Bond J, Settles M,
Roberts JS, Shields J, Jack L, Fox B.
Department of Psychiatry, School of Medicine,
Yale University, 950 Campbell Avenue,
06516, West Haven, CT, USA
Vaccine 2002 Jan 15;20(7-8):1196-1204


This randomized, double blind, placebo controlled, phase I clinical trial assessed the safety and immunogenicity of a therapeutic cocaine vaccine TA-CD in 34 former cocaine abusers: 8 at 13&mgr;g active vaccine, 10 at 82&mgr;g and 10 at 709&mgr;g, with two additional subjects getting placebo in each cohort. All got intra-muscular injections at 0-2 months and were monitored for safety and antibody production for 3 months. Of the 34 subjects 27 completed the full course of three injections, of these, only 24 returned for the final scheduled visit at day 84. The vaccine was well-tolerated and had no serious drug-related adverse events, although three subjects at the highest dose experienced brief post injection twitching. Fifteen subjects on TA-CD therapeutic vaccine were followed for 1 year. Antibody levels were correlated with vaccine dose and number of injections. Anti-cocaine antibodies were detected after the second injection, peaked at 3 months and declined to baseline by 1 year. Thus, the therapeutic vaccine was well tolerated with dose related increases in antibody levels, and a high proportion of patients recruited into the study were retained.

Vaccine dosage
Dopaminergic agents
The coke-craving brain
Vaccines against drugs
Cocaine vaccine IPC-1010
Monoamines, cocaine and rats
Cocaine and artificial enzymes
GBR12909 and normal subjects
Freebasing flies go hyperkinetic
Kappa receptors, dopamine D3 and cocaine

01 02 03 04 05 06 07 08 09 10 11 12
13 14 15 16 17 18 19 20 21 22 23 24

Future Opioids
BLTC Research
Wirehead Hedonism
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?

swan image
The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family